Monoclonal Anti-LAP2 (TMPO) antibody produced in mouse
SIGMA/L3414 - ~2 mg/mL, clone 6E10, purified immunoglobulin, buffered aqueous solution
Synonym: Anti-CMD1T; Anti-Cardiomyopathy, dilated, 1T, included; Anti-Lamina Associated Polypeptide 2; Anti-TMPO; Anti-Thymopoietin
MDL Number: MFCD02263594
Product Type: Chemical
Immunofluorescence HeLa cells were fixed and permeabilized with 4% Paraformaldehyde followed by 0.5% Triton X-100. Fixed cells were stained with 20 μg/mL Monoclonal Anti-LAP2 (TMPO), Clone: 6E10 (Cat. No. L3414). The antibody was developed using Goat Anti-Mouse IgG, ATTO 488 conjugate (Cat. No. 62197). Cells were counterstained with DAPI (blue) to stain nuclei.
Western Blotting Whole extract of K562 cells were separated on SDS-PAGE and probed with Monoclonal Anti-LAP2 (TMPO) antibody produced in Mouse, Clone: 6E10 (Cat. No. L3414). The antibody was developed using 1:5,000 Anti-Mouse IgG (Fab specific)-Peroxidase antibody produced in Goat (Cat. No. A9917). Lanes 1. 4 μg/mL antibody 2. Negative control
| antibody form | purified immunoglobulin |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | 6E10, monoclonal |
| concentration | ~2 mg/mL |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| isotype | IgG1 |
| mol wt | antigen 25 kDa (ζ isoform) |
| antigen 38 kDa (γ isoform, singlet or doublet) | |
| antigen 42 kDa (δ isoform) | |
| antigen 45 kDa (ε isoform) | |
| antigen 50 kDa (β isoform, singlet or doublet) | |
| antigen 76 kDa (α isoform) | |
| Quality Level | 200  |
| shipped in | dry ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunocytochemistry: suitable |
| microarray: suitable | |
| western blot: 2-4 μg/mL using whole extract of cultured human chronic myelogenous leukemia K562 cells. | |
| UniProt accession no. | P42166  |
| Application: | Monoclonal Anti-LAP2 (TMPO) antibody produced in mouse may be used in immunoblotting and immunocytochemistry. |
| Biochem/physiol Actions: | Thymopoietin β (TMPOβ)/lamina associated polypeptide 2 (LAP2) is putatively involved in functional nuclear architecture and cell cycle control. TMPOβ/LAP2 plays a key role in nuclear envelope (NE) disassembly and reassembly during mitosis and linking chromatin to the NE in interphase. TMPOβ/LAP2 binds lamin B1 and chromosomes in a phosphorylation dependent manner. TMPOβ/LAP2, either together with germ-cell-less (GCL) or alone, can repress the transcriptional activity of the elongation factor 2-dimerization partner (E2F-DP) heterodimer. TMPOα/LAP2 has a role in regulating the dynamics of the nuclear lamina and this interaction is required for nuclear growth after mitosis. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | Monoclonal Anti-LAP2 (TMPO) (mouse IgG1 isotype) is derived from the 6E10 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide (amino acids 29-50) common to the N-terminus of all TMPOs. Thymopoietin β (TMPOβ)/lamina associated polypeptide 2 (LAP2) is a type II integral protein of the inner nuclear envelope (NE). In mammalian cells, six alternatively spliced TMPO isoforms, designated α, β, β′, γ, δ, ε, and ζ have been isolated and characterized. LAP2/TMPO proteins is highly conserved in mammals and Xenopus. The expression of the various TMPO isoforms is ubiquitous, with higher levels in proliferative tissues. It has four domains: a hydrophilic C-terminus domain, a hydrophobic transmembrane domain, a NE targeting and lamina-binding domain, and a chromatin binding domain. TMPOβ/LAP2 contains two putative p34cdc2 kinase phosphorylation sites. |
| Immunogen: | synthetic peptide corresponding to amino acids 29-50 common to the N-terminus of all human TMPOs (isoforms α, β, γ, δ, ε, and ζ). |
| Physical form: | Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide. |
| Safety Statements | 23-24/25 |
| WGK Germany | - |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |